TY - JOUR
T1 - Epidemiology and Prevalence of Dyslipidemia Among Adult Population of Tehran
T2 - The Tehran Cohort Study
AU - Shafiee, Akbar
AU - Kazemian, Sina
AU - Jalali, Arash
AU - Alaeddini, Farshid
AU - Saadat, Soheil
AU - Masoudkabir, Farzad
AU - Tavolinejad, Hamed
AU - Vasheghani-Farahani, Ali
AU - Arita, Vicente Artola
AU - Sadeghian, Saeed
AU - Boroumand, Mohamamdali
AU - Karimi, Abbasali
AU - Franco, Oscar H.
N1 - Publisher Copyright:
© 2024 Academy of Medical Sciences of I.R. Iran. All rights reserved.
PY - 2024/2
Y1 - 2024/2
N2 - Background: Dyslipidemia is among the leading risk factors for cardiovascular diseases (CVDs), with an increasing global burden, especially in developing countries. We investigated the prevalence of dyslipidemia and abnormal lipid profiles in Tehran. Methods: We used data from 8072 individuals aged ≥ 35 from the Tehran Cohort Study (TeCS) recruitment phase. Fasting serum total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and triglyceride were measured. Dyslipidemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria, and high LDL/HDL was defined as a ratio > 2.5. The age-sex standardized prevalence rates were calculated based on the 2016 national census. Furthermore, the geographical distribution of dyslipidemia and lipid abnormalities was investigated across Tehran’s zip code districts. Results: The age-sex standardized prevalence was 82.7% (95% CI: 80.1%, 85.0%) for dyslipidemia, 36.9% (95% CI: 33.8%, 40.1%) for hypertriglyceridemia, 22.5% (95% CI: 19.9%, 25.4%) for hypercholesterolemia, 29.0% (95% CI: 26.1%, 32.1%) for high LDL-C, 55.9% (95% CI: 52.6%, 59.2%) for low HDL-C, and 54.1% (95% CI: 50.9%, 57.3%) for high LDL/HDL ratio in the Tehran adult population. The prevalence of dyslipidemia, low HDL-C, and high LDL/HDL ratio was higher in the northern regions, hypercholesterolemia was higher in the southern half, and high LDL-C was more prevalent in the middle-northern and southern areas of Tehran. Conclusion: We found a high prevalence of dyslipidemia, mainly high LDL/HDL in the Tehran adult population. This dyslipidemia profiling provides important information for public health policy to improve preventive interventions and reduce dyslipidemia-related morbidity and mortality in the future.
AB - Background: Dyslipidemia is among the leading risk factors for cardiovascular diseases (CVDs), with an increasing global burden, especially in developing countries. We investigated the prevalence of dyslipidemia and abnormal lipid profiles in Tehran. Methods: We used data from 8072 individuals aged ≥ 35 from the Tehran Cohort Study (TeCS) recruitment phase. Fasting serum total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and triglyceride were measured. Dyslipidemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria, and high LDL/HDL was defined as a ratio > 2.5. The age-sex standardized prevalence rates were calculated based on the 2016 national census. Furthermore, the geographical distribution of dyslipidemia and lipid abnormalities was investigated across Tehran’s zip code districts. Results: The age-sex standardized prevalence was 82.7% (95% CI: 80.1%, 85.0%) for dyslipidemia, 36.9% (95% CI: 33.8%, 40.1%) for hypertriglyceridemia, 22.5% (95% CI: 19.9%, 25.4%) for hypercholesterolemia, 29.0% (95% CI: 26.1%, 32.1%) for high LDL-C, 55.9% (95% CI: 52.6%, 59.2%) for low HDL-C, and 54.1% (95% CI: 50.9%, 57.3%) for high LDL/HDL ratio in the Tehran adult population. The prevalence of dyslipidemia, low HDL-C, and high LDL/HDL ratio was higher in the northern regions, hypercholesterolemia was higher in the southern half, and high LDL-C was more prevalent in the middle-northern and southern areas of Tehran. Conclusion: We found a high prevalence of dyslipidemia, mainly high LDL/HDL in the Tehran adult population. This dyslipidemia profiling provides important information for public health policy to improve preventive interventions and reduce dyslipidemia-related morbidity and mortality in the future.
KW - Dyslipidemia
KW - Epidemiology
KW - Hypercholesterolemia
KW - Hypertriglyceridemia
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85190578338&partnerID=8YFLogxK
U2 - 10.34172/aim.2024.10
DO - 10.34172/aim.2024.10
M3 - Article
C2 - 38619028
AN - SCOPUS:85190578338
SN - 1029-2977
VL - 27
SP - 51
EP - 61
JO - Archives of Iranian Medicine
JF - Archives of Iranian Medicine
IS - 2
M1 - 10.34172/aim.2024.10
ER -